Technology | 2019.04.01
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in the first patient in a Phase 1 clinical trial. TRPH-222 was originally developed by Catalent’s subsidiary Redwood Bioscience, Inc. using the proprietary SMARTag® platform, which provides optimized site-specific protein-modification and linker technologies. Triphase Accelerator obtained the worldwide rights to further develop this program and subsequently announced that Celgene had obtained the option to acquire all rights to the program as part of an expanded strategic collaboration.
(PRWeb April 01, 2019)
Read the full story at https://www.prweb.com/releases/triphase_accelerator_initiates_phase_1_clinical_trial_of_trph_222_in_b_cell_lymphoma/prweb16209620.htm
For more information, please visit
https://www.prweb.com/releases/triphase_[...]ell_lymphoma/prweb16209620.htm
Instagram is adding automatic in-app text translation - The Verge views: 1528
Instagram is adding automatic in-app text translation - The Verge views: 1499